Antileishmanial activity of nano-amphotericin B deoxycholate

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 376-380

  Manandhar, Krishna Das ^a   Yadav, Thakur Prasad ^b   Prajapati, Vijay Kumar ^a   Kumar, Subodh ^a   Rai, Madhukar ^a   Dube, Anuradha ^c   Srivastava, Onkar Nath ^b   Sundar, Shyam ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

In vitro; In vivo; Leishmania donovani; Nanomedicine; Nanoparticles; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DEOXYCHOLATE NANOPARTICLE; ANTILEISHMANIAL AGENT;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HAMSTER; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; MALE; MOUSE; NANOMEDICINE; NONHUMAN; PARASITE SURVIVAL; PARTICLE SIZE; SPLEEN; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CRICETINAE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MESOCRICETUS; MICE; NANOPARTICLES; SPLEEN;

EID: 47249160389     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn189     Document Type: Article

References (8)

1. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-7.
2. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3-19.
3. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-8.
4. Stauber LA, Franchino FM, Grun J. An eight-day method of screening compounds against Leishmania donovani in the golden hamster. J Protozool 1958; 5: 269-73.
5. Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70: 6284-93.
6. Larabi M, Yardley V, Loiseau PM et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003; 47: 3774-9.
7. Yoshiaki K. Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 2001; 47: 1-2.
8. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. Int J Pharm 2000; 196: 253-6.